Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

NCT06408688 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Immune checkpoint inhibitors plus Iscador® Qu.
DRUG: Immune Checkpoint Inhibitors

Sponsor

University Hospital, Basel, Switzerland